Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Anistreplase
Pharmaceutical drug

Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.

We don't have any images related to Anistreplase yet.
We don't have any YouTube videos related to Anistreplase yet.
We don't have any PDF documents related to Anistreplase yet.
We don't have any Books related to Anistreplase yet.
We don't have any archived web articles related to Anistreplase yet.

Uses

Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.1 Early treatment gives better outcomes.2

History

Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.345

References

  1. Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. https://www.bmj.com/content/312/7025/212.full ↩

  2. Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. https://www.bmj.com/content/312/7025/212.full ↩

  3. Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585. https://www.bmj.com/content/312/7025/212.full ↩

  4. Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1239197 ↩

  5. Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1059832 ↩